ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines, and diagnostics. ACRO established long-term collaborations with big pharma like Pfizer, Novartis, and Johnson & Johnson, and well-known academic institutes. As the viruses is constantly mutating, new variants are expected to potential increase transmissibility and severity of COVID-19. ACROBiosystems has developed a collection of recombinant antigens for these emerging variants. ACROBiosystems recently launched a ready-to-use neutralizing antibody titer serologic assay kit (Cat.No. TAS-K022) which can sensitively and specifically detect COVID 19 neutralizing antibodies within 2 hours. The kit performance shows high correlation with FDA-EUA approved ELISA kit! The core technology platforms focus on mammalian cell-based recombinant protein production and process development. We have multiple offices and branches in North America, Europe, and Asia, and we are proud of serving customers from over 50 countries.